Children
Efavirenz (Sustiva) is approved in the European Union and the United States for use in HIV-infected children aged three years and over. For children who weigh less than 40kg, dose is adjusted for weight. A syrup formulation is available for children who find capsules difficult to take.
ACTG 382 is an ongoing 48-week study of efavirenz in combination with nelfinavir (Viracept) and two nucleoside reverse transcriptase inhibitors (NRTIs) in 57 children with HIV. Results at one year showed similar safety and efficacy to adults. Rash was more common and more severe in this group than in adults, although central nervous system side-effects appear to be milder[1][2][3].
Efavirenz has not been evaluated in children under three years of age or below 13kg in weight.
latest aidsmap news
- 'ART as prevention tool' policy announced for British Columbia
- <i>The Lancet</i>: HIV is a global disaster
- Important changes to nevirapine dosing advice made by FDA
- Fatty liver in patients with HIV associated with metabolic abnormalities
- Most HIV infections in Zambia and Rwanda happen in marriage: prevention programmes for couples recommended
- HIV-positive Caribbean people in the UK experience high levels of stigma
- Poverty and unemployment common amongst HIV-positive Londoners
- Risk of death for people with HIV now similar to that seen in the general population
- Simple, cheap test an accurate measure of hardening of the arteries in patients with HIV
- Asymptomatic anal HPV infection more common than thought in heterosexual men